Alisa Pantanakasame Young

Dr. Alisa Pantanakasame Young

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2014
Verified
Journal Article
Closed access
MCMaria Syl D De La Cruz
Maria Syl D De La Cruz
AYAlisa Pantanakasame Young
Alisa Pantanakasame Young
MRMack T Ruffin
Mack T Ruffin

18 January 2025 in Preventive Medicine Reports
Verified
Journal Article
Open access
AYAlisa Pantanakasame Young
Alisa Pantanakasame Young
MOMutiya Olorunfemi
Mutiya Olorunfemi
LMLeigh Morrison
Leigh Morrison
SKScott A. Kelley
Scott A. Kelley
ALAnna Laurie
Anna Laurie
Diane M. HarperDiane M. Harper
Diane M. Harper
The Food and Drug Administration (FDA) in the US approved primary human papillomavirus (HPV) testing for speculum-based cervical cancer screening ten years ago and, in May 2024, approved the self-collection technique. Our study defines the kappa agreement between self- and speculum-based collection techniques for 15 types of high-risk HPV. Additionally, we describe the sensitivity and specificity ratios for HPV testing using both collection methods. Participants recruited in 2020-2022 included 97 colposcopy attendees and 96 routine primary care screening attendees aged 30-65, who agreed to self-sample before their clinically scheduled speculum-based exam. Prevalence-based kappa calculated agreement, sensitivity and specificity ratios calculated accuracy using the cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) threshold. The average ages were 45.9 (SD 10.5) and 46.2 (SD 11.0) years for the colposcopy and primary care attendees, respectively. HPV 16, 68, and 39 were the most common types detected. The lower bound of the 95 % Cl for kappa calculations was above 0.81, indicating almost perfect agreement across all HPV genotypes. The sensitivity and specificity ratios were consistent at 1.0 across both collection methods. The HPV positivity rate was significantly higher among colposcopy attendees at 66 % (64/97), compared to 14 % (13/96) among routine primary care screeners. The study identified 17 women with CIN2 + . Primary HPV screening with self-collection is equivalent to speculum-based collection among people aged 30-65. The findings emphasize the utility of self-collection in identifying high-grade lesions and the consistency of HPV detection across different collection methods.

30 August 2025 in Preventive Medicine Reports
Verified
Journal Article
Open access
AYAlisa Pantanakasame Young
Alisa Pantanakasame Young
MOMarie Claire O'Dwyer
Marie Claire O'Dwyer
RSRoger Smith
Roger Smith
DCDongru Chen
Dongru Chen
ASAnanda Sen
Ananda Sen
Diane M. HarperDiane M. Harper
Diane M. Harper
Urine can provide a non-invasive screening method for high-risk human papillomavirus (hrHPV) infections. We aimed to compare detection rates of hrHPV and cervical intraepithelial neoplasia grade two or worse (CIN2+) using first-void urine (FVU) and clinician-collected cervical samples. We assessed whether the time of day of FVU collection impacts hrHPV detection. We recruited 188 participants, 30–65 years, before their colposcopy or routine screening from September 2020 through February 2022. Each collected FVU twice on the same day: at home and in the clinic before their appointments. We used prevalence-adjusted bias-adjusted kappa (PABAK) scores to compare hrHPV type-specific agreement, followed by McNemar's Exact test. We assessed both absolute and relative sensitivity and specificity to evaluate the accuracy of the collection techniques in predicting CIN2+ by hrHPV type. 95 hrHPV infections were detected in 70/188 (37.2 %) women. The PABAK agreement for hrHPV16 detection between FVU and the speculum was 0.95 (95 % CI: 0.91, 1.0). The agreement for hrHPV detection was almost perfect between home or clinic urine collection and the speculum specimen. The accuracy of CIN2+ detection measured by the sensitivity ratio of the clinic first-void specimen compared to the speculum specimen for hrHPV16 was 1.00 (0.62, 6.20). Most specificity ratios for all other hrHPV types were anchored at 1.0 with narrow confidence intervals. The time of day for FVU gave similar “any hrHPV” detection rates (27.5 % vs 32 %, p > 0.05). FVU hrHPV testing offers a potential cervical cancer screening alternative for women who cannot tolerate other collections.

14 January 2026 in Preventive Medicine
Verified
Journal Article
Closed access
KUKeely K. Ulmer
Keely K. Ulmer
LSLisa F. Soltani
Lisa F. Soltani
IAIlana Addis
Ilana Addis
AYAlisa Pantanakasame Young
Alisa Pantanakasame Young
Diane M. HarperDiane M. Harper
Diane M. Harper

28 August 2016
Verified
Book Chapter
Closed access
PDF file
AYAlisa Pantanakasame Young
Alisa Pantanakasame Young
MCMaria Syl D. de la Cruz
Maria Syl D. de la Cruz
MRMack T. Ruffin
Mack T. Ruffin

14 February 2015
Verified
Book Chapter
Closed access
PDF file
AYAlisa Pantanakasame Young
Alisa Pantanakasame Young
MCMaria Syl D. de la Cruz
Maria Syl D. de la Cruz
MRMack T. Ruffin
Mack T. Ruffin